HALFLYTELY
LOE Approachingbisacodyl; polyethylene glycol 3350; potassium chloride; sodium bicarbonate; sodium chloride
NDAORALFOR SOLUTION, TABLET, DELAYED RELEASE
Approved
May 2004
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
3
Data completeness
2/8 — Basic
Drug data last refreshed 19h ago · AI intelligence enriched 2mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
HALFLYTELY is a bowel preparation solution combining polyethylene glycol 3350 (osmotic laxative), bisacodyl (stimulant laxative), and electrolytes for gastrointestinal cleansing prior to colonoscopy or other GI procedures. The formulation works by inducing rapid intestinal transit and fluid secretion to clear the colon. It is administered orally as a divided-dose regimen to minimize patient tolerability burden.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30%), indicating a mature brand likely in defensive/optimization phase with stable to contracting team resources.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (3)
Safety and Efficacy of OsmoPrep® Tablets Versus HalfLytely® and Bisacodyl Tablet Bowel Prep Kit for Colon Cleansing
Started Sep 2011
2,154 enrolled
Colon Cleansing
Investigation of PicoPrep Versus HalfLytely for Bowel Preparation for Colonoscopy - Day Before PicoPrep
Started May 2010
603 enrolled
Bowel Preparation
Investigation of PicoPrep Versus HalfLytely for Bowel Preparation for Colonoscopy - Split Dose PicoPrep
Started May 2010
608 enrolled
Bowel Preparation
Career Relevance
Working on HALFLYTELY offers limited growth trajectory and career advancement given its LOE-approaching status and mature market position. Roles are primarily focused on defensive marketing, managed care negotiation, and cost-competitive positioning rather than innovation.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.